Ergosterol, the principal sterol in fungal cell membranes, is the natural precursor of vitamin D₂. Ultraviolet exposure opens the molecule’s B-ring to form previtamin D₂, which then undergoes thermal isomerization to vitamin D₂. This mechanism allows mushrooms to become a controllable, non-animal source of the vitamin, but exposure must be managed carefully. Continued or excessive irradiation can generate lumisterol₂, tachysterol₂, vitamin D₄ and other photoproducts rather than improving the desired fraction. Reported vitamin D₂ concentrations consequently depend not only on ergosterol abundance but also on wavelength, dose, irradiance, exposure time, moisture, temperature, particle size, matrix structure and the geometry of the irradiated material.

The feedstock is itself highly variable. Species, strain, developmental stage, anatomical part, cultivation conditions, light exposure, storage and drying can all change ergosterol content and extractability. Processing can also leave a substantial residue: non-marketable caps, stipes, trimmings and irregular fruiting bodies may account for up to 30% of production mass. These materials retain ergosterol and offer a possible alternative to using edible mushrooms specifically for nutrient production. Their composition nevertheless varies, and the chitin-, β-glucan- and protein-rich cell wall can restrict solvent penetration. Drying, milling, steaming, ultrasound, microwave, enzymatic and other pretreatments can improve access to membrane-associated sterols, but the benefits depend on the species and the extraction process that follows.

Conventional Soxhlet, maceration and heat-assisted extraction remain useful benchmarks because they are established, although they may require hours of heating, substantial solvent and several downstream steps. Their weakness is not necessarily poor recovery, but the combined burden of long treatment, thermal exposure, solvent evaporation and purification. Ultrasound-assisted extraction can shorten the process and improve mass transfer through cavitation. In one study of industrial button-mushroom stalks, ultrasound at 25 °C increased ergosterol extraction by as much as roughly twofold relative to mechanical agitation, while 96% ethanol produced about twice the yield of 70% ethanol. This illustrates a recurring feature of intensified extraction: physical treatment and solvent composition cannot be optimized independently.

Microwave-assisted extraction offers another rapid route. In button-mushroom processing by-products, approximately 19.4 minutes at 132.8 °C and 1.6 grams of dry biomass per liter produced 556.1 milligrams of ergosterol per 100 grams, comparable to conventional recovery in much less time. Pressurized liquid extraction can likewise use short cycles and food-grade ethanol, although it demands pressure-rated equipment and controlled depressurization. Supercritical CO₂ extraction is particularly useful for separating lipophilic sterols from mushroom matrices. In one optimized button-mushroom process, the point that maximized ergosterol purity did not coincide with the point that maximized recovery, demonstrating that a high total extract yield can come at the cost of co-extracted material and more demanding downstream separation.

Enzymatic pretreatment may be particularly useful with supercritical CO₂. In a comparative study, chitinase increased the ergosterol concentration in a shiitake extract to 337.53 milligrams per gram, outperforming the effects of microwave and ultrasound pretreatments under the tested conditions. Deep eutectic solvents and natural deep eutectic solvents offer another route because their properties can be tailored and reused. A proline–levulinic acid system was recycled for seven shiitake-stem extraction cycles without a significant loss in extraction efficiency, while a menthol-based system supported ultrasound-assisted ergosterol recovery, ultraviolet conversion and stabilization in the same medium. The integrated system achieved 85.41% ergosterol extraction efficiency and a 4.08% vitamin D₂ yield, but these findings remain laboratory results rather than commercial performance.

Process integration also changes how irradiation must be controlled. Irradiating whole mushrooms before extraction avoids solvent handling but can be restricted by poor light penetration, whereas irradiation of an extract improves precursor accessibility yet adds solvent-dependent photochemistry and separation steps. Studies of mushroom extracts indicate that 254-nanometre light can convert ergosterol more effectively than 365-nanometre light, although broader spectra may act faster while producing more unwanted isomers. Intense pulsed light increased vitamin D₂ in shiitake powder from 4.18 to 100.82 micrograms per gram under the most intensive reported condition. Particle size must also be optimized rather than minimized without limit: one button-mushroom powder preparation achieved a 2.59% vitamin D₂ yield at a median particle size of 130–140 micrometres, reflecting a balance among surface area, porosity, light shielding and optical penetration.

Scale-up is the principal gap identified by the review. Increasing the size of a batch can alter acoustic-field distribution, electromagnetic heating, solvent flow, heat and mass transfer, pressure drop and irradiation geometry. A larger supercritical-CO₂ system for shiitake, using a six-liter vessel and two 1.6-liter separators, produced a lower overall extraction yield than smaller systems under similar conditions but generated fractions in which ergosterol accounted for as much as about 53% of the extract. The larger apparatus also separated sterol-rich fractions of different compositions. Such results show why yield, enrichment, productivity and fractionation must all be monitored during enlargement. Larger ultrasound systems also require careful control of power density and energy distribution, and flow-through configurations are often more practical than simply scaling a laboratory batch.

Environmental and economic assessments expose further constraints. A cradle-to-gate life-cycle assessment of an ergosterol-rich extract from mushroom residues attributed roughly 31–32% of potential damage to ultrasound-assisted ethanol extraction, 31–32% to evaporation and 19–20% to lyophilization, with electricity contributing as much as 70–85% of impacts under some allocation approaches. Locally generated photovoltaic electricity reduced impacts by up to about 50% in the assessed scenario, whereas osmotic dehydration before lyophilization produced a much smaller reduction of around 9%. A separate laboratory-based economic assessment estimated production costs of €2.43 per gram for an ergosterol-rich extract and €8.28 per gram for a vitamin D₂-rich extract; ethanol recovery reduced those estimates by about 47% and 39%, respectively, with the vitamin D₂-rich figure falling to €5.04 per gram. These are process-specific estimates, not validated industrial prices, but they identify solvent recovery, electricity, purification and the extra conversion step as decisive variables.

Patent activity suggests that commercial concepts are developing faster than public pilot-scale evidence. The targeted search identified 50 patents directly related to mushroom ergosterol or vitamin D₂ processing, plus eight downstream-use applications. Early inventions centered on ultraviolet treatment of dried shiitake, while later patents addressed fresh mushrooms, controlled humidity and temperature, conveyors, vibrating beds, pulsed light and irradiation integrated into drying systems. More recent approaches combine extraction with conversion, including ethanol extraction followed by ultraviolet treatment, vegetable-oil extraction of irradiated mushrooms, supercritical-CO₂ purification and direct irradiation of natural deep eutectic solvent extracts. The next essential step is not another isolated demonstration of extraction yield, but pilot-scale validation of complete process chains with standardized mass and energy balances, product-stability testing, solvent accounting and simultaneous techno-economic and life-cycle assessment.

Subject of Research: Process intensification and scale-up of ergosterol and vitamin D2 recovery from mushrooms

Article Title: Advanced recovery of ergosterol- and vitamin D2-rich fractions from mushrooms: process intensification and scale-up challenges

Article References: Pastor, K., Vladic, J., & Nastić, N. (2026). Advanced recovery of ergosterol- and vitamin D2-rich fractions from mushrooms: process intensification and scale-up challenges. Frontiers in Nutrition, 13, Article 1987834. https://doi.org/10.3389/fnut.2026.1987834

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1987834

Keywords: mushrooms, ergosterol, vitamin D2, UV photoconversion, process intensification, supercritical CO2 extraction, deep eutectic solvents, ultrasound extraction, scale-up, life-cycle assessment, Advanced, recovery

The result was specific rather than universal. Silybin combined with voriconazole was synergistic against five of the 10 isolates, while the combination with itraconazole was synergistic against three. No synergy was detected with fluconazole, and one isolate showed antagonism with silybin plus itraconazole. Compared with the silybin-fluconazole reference, the difference in synergy rate was statistically significant only for the posaconazole combination after Holm adjustment. The exact 95% confidence interval for the 70% posaconazole-silybin synergy rate was 34.8% to 93.3%, emphasizing the preliminary scale of the evidence.

Mechanistic experiments focused primarily on the seven isolates that responded synergistically to posaconazole plus silybin. The combination lowered cellular ergosterol more than posaconazole alone in all seven, with significant differences ranging from p = 0.0291 to p less than 0.0001. An eighth isolate classified as showing no interaction did not exhibit a significant change. Ergosterol is a major fungal membrane sterol, and the azole target CYP51 participates in its synthesis. The findings are consistent with interference in membrane sterol production, but the researchers did not establish that silybin directly inhibits CYP51 or that this mechanism causes the observed synergy.

Reactive oxygen species measurements provided another correlate of antifungal action. In six of eight tested isolates, posaconazole plus silybin produced higher fluorescence than posaconazole alone, indicating greater intracellular reactive oxygen species accumulation; the differences were significant at p = 0.0217. Two isolates did not show significant increases. The authors were careful to distinguish association from mechanism: because the experiments did not test whether neutralizing reactive oxygen species reversed the combination effect, the elevated signal cannot yet be described as the definitive mediator of fungal killing or reduced biofilm survival.

Biofilm assays produced convergent results across developmental stages. In the crystal-violet assay, posaconazole alone inhibited biofilm formation by 13.7% to 61.5%, depending on the isolate. Adding silybin raised inhibition to 24.2% to 79.7%. The combination was significantly more effective than posaconazole alone in six of eight strains, improving inhibition by 16.5 to 46.5 percentage points, although no significant difference was detected in strains 382 and 390. An XTT assay, which measures fungal metabolic activity, likewise found stronger suppression by the combination in five of eight isolates, all with p less than 0.0001; three strains showed no significant difference between treatments.

The combination also affected established microbial communities. In SYTO9 and propidium iodide staining assessed by confocal laser scanning microscopy, posaconazole alone had limited activity against preformed mature biofilms. Posaconazole plus silybin decreased green fluorescence from viable cells and increased red fluorescence associated with membrane-compromised or dead cells. These observations indicate lower biofilm-cell viability after combination treatment. Together with the formation and metabolic assays, the results show activity against both developing and mature biofilms, but the microscopy was performed in laboratory culture rather than in an infected host or medical device.

Real-time quantitative PCR suggested that the combination altered several pathways relevant to adhesion, biofilm regulation, cell-wall integrity, and sterol synthesis. Compared with posaconazole monotherapy, the combination significantly reduced expression of bcr1, mkc1, erg2, and als5 in all seven synergistic isolates. Expression of efg1 fell in six, erg11 in six, and scf1 in five. The non-synergistic isolate showed significant reductions only in mkc1 and als5. These measurements were made in planktonic cells, so they may not represent gene activity within a biofilm. The authors also noted that altered messenger RNA levels do not by themselves prove loss of adhesion, biofilm formation, or other biological functions.

Silybin is a flavonolignan obtained from milk thistle and is used as a medicinal agent and dietary supplement. Posaconazole is an established antifungal, and each has an individual safety profile. That does not establish the safety or effectiveness of their combination. No direct cytotoxicity testing was performed in mammalian cells, no animal efficacy or safety study was conducted, and no clinical outcomes were evaluated. The experimental concentration is also a major translational obstacle: the lowest silybin concentration producing synergy was 4 micrograms per milliliter, compared with an effective in-vivo concentration of approximately 0.0965 micrograms per milliliter and typical oral exposure constrained by silybin’s reported absolute bioavailability of about 0.45%.

Taken together, the study provides proof-of-concept evidence for a combination that was most consistently synergistic with posaconazole in a small collection of multidrug-resistant C. auris isolates. Its effects included reduced ergosterol, increased reactive oxygen species, stronger inhibition of biofilm formation and metabolism, reduced viability in mature biofilms, and lower expression of selected biofilm- and sterol-associated genes. The findings support further investigation rather than immediate clinical use. Larger and more diverse strain panels, direct mechanistic tests, mammalian-cell toxicity studies, animal pharmacodynamic experiments, and improved silybin formulations would be needed to determine whether the laboratory synergy can be reproduced in vivo and translated into a treatment that balances efficacy, exposure, and safety.

Subject of Research: In-vitro synergistic antifungal and antibiofilm effects of silybin combined with posaconazole against Candida auris.

Article Title: In vitro synergistic antifungal activity of silybin-posaconazole combination against Candida auris

Article References: Peng, M., Zhu, X., Hu, Q., Fan, Y., Mao, Y., Chen, X., Qin, H., Zhang, H., & Sun, Y. (2026). In vitro synergistic antifungal activity of silybin-posaconazole combination against Candida auris. Frontiers in Microbiology, 17, Article 1881511. https://doi.org/10.3389/fmicb.2026.1881511

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1881511

Keywords: Candida auris, silybin, posaconazole, antifungal synergy, drug resistance, biofilms, ergosterol, oxidative stress, azole resistance, in-vitro research, vitro, synergistic

When Reticulitermes flavipes workers encounter spores of Metarhizium adhering to a nestmate’s cuticle, they respond with brief bouts of rapid, whole-body shaking, a behavior the researchers call longitudinal oscillatory movement. This alarm display functions as a call for help, soliciting allogrooming from nearby colony members. Workers use their mouthparts to strip conidia from each other’s bodies, and the ingested spores are effectively destroyed, aided by salivary antimicrobial compounds including beta-1,3-glucanases and a small, cysteine-rich antifungal peptide called termicin. The critical open question has been which molecular signature, or pathogen-associated molecular pattern, actually triggers this rapid hygienic response. Ergosterol, an essential component of fungal membranes, was a leading candidate, particularly after earlier work showed that applying ergosterol to the cuticle of the Formosan subterranean termite Coptotermes formosanus elicited increased allogrooming.

To test this hypothesis rigorously, the team collected thirteen clonally propagated Metarhizium isolates from soils near active termite foraging sites across five US states, representing three species: Metarhizium robertsii, M. brunneum and M. guizhouense. Species and strains were confirmed by sequencing the translation elongation factor 1-alpha gene along with ITS and intergenic spacer regions. The researchers then quantified ergosterol in each isolate’s conidia using a saponification and spectrophotometric method originally developed for measuring ergosterol in Candida, calculating sterol content as a percentage of wet spore weight and correcting for the late pathway intermediate 24(28)-dehydroergosterol, which absorbs at a different wavelength.

The behavioral experiments produced a striking and initially counterintuitive result. In preference assays, termites given a choice between filter paper halves treated with ergosterol, cholesterol or solvent alone aggregated on the sterol-treated sides, but only ergosterol significantly elevated alarm shaking and allogrooming. Filter papers treated with methanol extracts of ergosterol from conidia also triggered alarm responses that correlated positively with the ergosterol content of the source isolates. Yet when termites were challenged with intact, living conidia, the intensity of the alarm response was not positively correlated with ergosterol content at all. Instead, the relationship trended in the opposite direction, suggesting that while ergosterol can serve as a recognition cue on its own, it is not the initial signal that alerts termites to dangerous contamination on a nestmate’s body.

Even more revealing was the correlation between ergosterol and pathogenicity. Across the thirteen isolates, spore ergosterol content was significantly and positively associated with the hazard ratio of death in Cox regression survival analyses, meaning that isolates richer in membrane ergosterol were more lethal to termites, not less. Adhesion assays ruled out the possibility that the most alarming isolate simply deposited more spores on the cuticle, and thin-layer chromatography showed no peroxidation or amino acid acylation of the sterol that might have altered its detectability. The picture that emerged was of a fungus in which high ergosterol somehow confers a survival advantage during the critical early hours after contact with a termite host.

The key to that advantage appears to lie in termicin, the termite’s principal antifungal weapon. When the researchers incubated conidia from each isolate in a five micromolar solution of recombinant R. flavipes termicin, the peptide’s fungicidal activity varied dramatically across isolates and correlated strongly with both virulence and ergosterol content. Termicin was most effective against the most lethal isolates, those with the highest ergosterol levels, and least effective against the least alarming, low-ergosterol strains. In vivo confirmation followed: pretreating conidia of the high-ergosterol isolate MD 002 with termicin significantly improved termite survival over fourteen days, while the same treatment offered no protection against the low-ergosterol isolate MD 353. Because termicin is an amphipathic peptide believed to disrupt fungal membranes, membrane ergosterol content plausibly determines how vulnerable a spore is to this assault.

Together, these findings sketch a mechanistic model of coupled, counterbalancing traits. Fungal cell wall integrity is known to be influenced by membrane ergosterol, and studies of antifungal drugs that block ergosterol synthesis show that reducing membrane sterol is compensated by reinforcing the cell wall. The Towson team proposes that Metarhizium isolates with lower membrane ergosterol develop cell walls richer in whatever unidentified pathogen-associated molecular pattern termites actually detect, making those spores easier to recognize and triggering vigorous allogrooming. Conversely, isolates with high ergosterol are harder for termicin to kill but present a weaker initial alarm signal. The fungus thus faces a genuine trade-off between a shield that protects against the peptide weapon and a signal that betrays it to the colony’s hygiene patrol, and the termites appear to have adaptively exploited exactly this vulnerability.

The evolutionary dimension of the story is equally compelling. Previous work documented a recent selective sweep for an advantageous termicin variant in sympatric populations of R. flavipes and R. virginicus in Maryland, and the two species respond differently to M. brunneum and M. robertsii, hinting at co-adaptation to local fungal lineages. In the new study, genetic distances between Metarhizium isolates correlated significantly with differences in the alarm responses their conidia elicited, even after controlling for collection latitude, indicating that the true recognition cue has diverged along with fungal phylogeny. Ergosterol content, by contrast, showed no correlation with genetic distance, suggesting it is a more plastic trait shaped by environmental conditions. Consistent with that idea, prior research on Argentine ants found that serial laboratory exposure to small ant groups drove Metarhizium to reduce its ergosterol and evade social immunity, a shift that would simultaneously increase the wall-based signal termites detect.

Ergosterol may also play a subtler secondary role in the hygiene cascade. The authors speculate that when termicin disrupts the membranes of high-ergosterol spores, released sterol could then act as a secondary elicitor, amplifying aggregation and allogrooming precisely when the initial wall-based alarm is weak. Residual ergosterol has been detected on the cuticles of C. formosanus workers an hour after Metarhizium exposure, lending plausibility to this compensation mechanism. Candidate molecules for the primary cue include cell wall beta-glucans, although inhibiting termite beta-1,3-glucanases did not reduce allogrooming in earlier experiments, leaving the identity of the true trigger unresolved. What is clear is that termite survival rests on a finely tuned balance between a behavioral response that is energetically costly and a peptide weapon whose effectiveness varies with the biochemistry of each fungal strain it meets.

Beyond its elegance as an evolutionary case study, the work carries practical implications. Metarhizium species are widely deployed as biological control agents against termites and other soil pests, and understanding why some isolates fail, namely because they trigger strong social immunity while resisting termicin, could guide the selection or engineering of strains that slip past termite defenses. Conversely, the finding that ergosterol content can shift plastically under selection pressure suggests that pathogens can rapidly adapt to dense, patchily distributed social insect populations. For now, the termites hold their ground through a two-layered strategy: an unidentified cell wall signal that sounds the alarm, and a membrane-targeting peptide that strikes hardest at the strains most adept at staying quiet. The arms race beneath the forest floor, it turns out, is negotiated one sterol molecule at a time.

Subject of Research: The role of ergosterol in termite social immunity and fungal pathogen detection against Metarhizium infections

Article Title: The influence of ergosterol on termites’ defenses against Metarhizium infections

Article References: Rosenbloom, J. H., Luitel, B., & Bulmer, M. S. (2026). The influence of ergosterol on termites’ defenses against Metarhizium infections. The Science of Nature, 113(6), Article 130. https://doi.org/10.1007/s00114-026-02183-3

Image Credits: AI Generated

DOI: 10.1007/s00114-026-02183-3

Keywords: ergosterol, termites, Metarhizium, social immunity, allogrooming, termicin, antifungal peptide, pathogen-associated molecular pattern, Reticulitermes flavipes, entomopathogenic fungus, fungal cell membrane, host-pathogen coevolution

A central puzzle in resistance biology is whether different fungal isolates traveling toward the same resistant phenotype take the same genetic road or different ones. If resistance usually arises through a shared, predictable set of mutations, then diagnostic assays targeting those mutations could catch resistant strains early, and drug development could focus on countering a small number of mechanisms. If, however, resistance can be assembled through many alternative mutational routes, surveillance becomes far harder, because each new resistant isolate may carry a unique genomic signature. A new study published in PLOS One by Mounzer Abbas, Nour Fattouh, Christy Chedraoui, Setrida El Hachem, Tsolaire Sourenian, Ibrahim Bitar, and Roy A. Khalaf set out to answer exactly this question for C. albicans, asking whether antifungal resistance follows convergent or divergent adaptive pathways at the genetic level.

The team’s experimental design was deliberately controlled. They generated six laboratory-induced fluconazole-resistant isolates and six caspofungin-resistant isolates and then subjected all twelve to whole-genome sequencing, paired with a battery of phenotypic tests measuring traits tied to pathogenicity, including ergosterol content, efflux pump activity, chitin levels, and biofilm formation. By evolving resistance in the laboratory under defined conditions, the researchers could compare resistant isolates against their susceptible progenitors and attribute specific genomic changes to the resistance process itself, rather than to the heterogeneous backgrounds of clinical strains collected from different patients.

The fluconazole-resistant isolates told a story of remarkable phenotypic convergence. Every one of the six showed increased ergosterol production, a classic response to azole pressure, because the fungus compensates for the partial inhibition of its ergosterol biosynthesis pathway by pushing the pathway harder. Every one also displayed elevated activity of ATP-binding cassette transporter efflux pumps, the molecular pumps that actively expel fluconazole from the cell before it can reach its target. In other words, at the level of physiology, all six isolates had arrived at essentially the same resistant state, combining target-pathway compensation with active drug export.

When the researchers looked at the underlying DNA sequences, however, the picture became more complicated. Certain mutations recurred across all the fluconazole-resistant isolates, including variants in ERG24, a gene encoding an enzyme in the ergosterol biosynthesis pathway, and a specific substitution, SOD6 S225P, in a superoxide dismutase gene that appears in every resistant isolate. These recurrent changes suggest genuine convergent evolution, with the same amino acid substitutions arising independently in separate lineages because they confer a selective advantage under azole stress. Yet other mutations, such as ERG11 T128K in the direct target of fluconazole, appeared in some isolates but not others, indicating that the resistance program is assembled from a mixture of shared core mutations and isolate-specific accessory changes.

The caspofungin-resistant isolates presented an equally instructive contrast. All six shared a common resistance strategy centered on the cell wall, but the genetic implementation differed from isolate to isolate. Each carried mutations in CHS3, the gene encoding chitin synthase 3, the enzyme responsible for the bulk of chitin synthesis in C. albicans. Because caspofungin blocks beta-glucan synthesis, fungi can compensate by reinforcing their walls with extra chitin, and elevated chitin is a well-established mechanism of echinocandin tolerance. Strikingly, although every resistant isolate increased its chitin content, the magnitude of that increase varied among isolates, tracking the diversity of CHS3 mutations each had acquired. A shared adaptive strategy, chitin reinforcement, was thus implemented through distinct genetic variants with quantitatively different outcomes.

Beyond point mutations, the sequencing analysis, performed with the Yeast Mapping Analysis Pipeline, or YMAP, revealed large-scale chromosomal rearrangements in the resistant isolates. These structural changes, which can include aneuploidy and segmental duplications, add an important dimension to the resistance story because they can amplify the dosage of resistance-conferring genes or alter the copy number of entire chromosomes carrying drug targets. The finding underscores that resistance evolution in C. albicans is not simply a matter of accumulating single-nucleotide changes; genome architecture itself is a mutable substrate, and rearrangements can contribute materially to the acquisition of the resistant phenotype.

Perhaps the most biologically intriguing result concerns what resistance costs. Many of the resistant isolates, for both drugs, showed decreased biofilm formation and reduced virulence-associated characteristics compared with their susceptible counterparts. Biofilms, the surface-attached microbial communities that are particularly problematic on catheters and other medical devices, are energetically expensive structures, and the same cellular remodeling that confers drug resistance appears to impose fitness trade-offs on other traits. This pattern suggests that resistance and virulence are not independently adjustable dials; rather, the evolutionary pressure to survive drug exposure can force the fungus to sacrifice aspects of its pathogenic arsenal, a phenomenon with potential implications for how resistant infections behave in patients.

Taken together, the study delivers a nuanced verdict on the convergence question: convergent phenotypes, divergent genetics. The resistant isolates converged on shared physiological strategies, ergosterol elevation and efflux for fluconazole, chitin reinforcement for caspofungin, and even on some recurrent point mutations, but the full set of genomic changes underlying each resistant phenotype was largely isolate-specific, and chromosomal rearrangements added further heterogeneity. For clinicians and epidemiologists, this means that sequencing a single canonical mutation will not reliably identify all resistant strains, and that resistance surveillance must contend with a shifting mosaic of genetic mechanisms. For drug developers, the fitness trade-offs observed here hint that combination strategies targeting both resistance mechanisms and virulence pathways could exploit the costs that resistance imposes.

The work also highlights the value of laboratory evolution experiments as a complement to clinical genomics. By observing resistance as it emerges under controlled conditions, researchers can distinguish cause from correlation, identify recurrent mutations that represent genuine adaptive solutions, and measure the phenotypic consequences of specific genetic changes. As antifungal resistance continues to spread globally and the pipeline of new antifungal agents remains thin, studies of this kind provide an essential map of the evolutionary landscape that future drugs and diagnostics will need to navigate, one in which the same destination can be reached by many different roads.

Subject of Research: Genetic mechanisms of fluconazole and caspofungin resistance evolution in Candida albicans

Article Title: Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans

Article References: Abbas, M., Fattouh, N., Chedraoui, C., El Hachem, S., Sourenian, T., Bitar, I., & Khalaf, R. A. (2026). Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans. PLOS One, 21(10), e0360234. https://doi.org/10.1371/journal.pone.0360234

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360234

Keywords: Candida albicans, antifungal resistance, fluconazole, caspofungin, whole-genome sequencing, ergosterol, efflux pumps, chitin, biofilm, chromosomal rearrangements, evolutionary convergence, virulence trade-offs

The biological rationale behind the study rests on one of glioblastoma’s most distinctive metabolic vulnerabilities. Unlike many tissues that synthesize their own cholesterol, glioblastoma cells are heavily co-dependent on exogenous cholesterol to fuel oncogenic signaling and the relentless membrane biogenesis required for rapid proliferation. This dependency places the liver X receptor beta (LXRβ), the principal transcriptional regulator of cholesterol efflux in the central nervous system, at the center of a promising therapeutic strategy. Activating LXRβ in tumor cells forces them to export cholesterol, depleting intracellular pools and effectively starving the cancer of a raw material it cannot easily replace.

The catch has always been selectivity. LXR receptors come in two flavors, LXRα and LXRβ, and indiscriminate activation of both has historically caused hepatotoxicity through excessive lipogenesis in the liver, where LXRα dominates. Early synthetic agonists such as T-0901317 activated both isoforms and were never suitable for chronic cancer therapy. On top of that, any drug aimed at a brain tumor must cross the blood-brain barrier, a formidable filter that excludes most large or polar molecules. Developing an LXRβ-selective, brain-penetrant agonist has therefore remained an unsolved challenge in neuro-oncology, and it is precisely the problem the Chinese team set out to crack with machine learning rather than traditional medicinal chemistry.

Their solution is a multi-layered computational pipeline that combines several complementary artificial intelligence approaches. At its core sits a machine learning-based quantitative structure-activity relationship (QSAR) model trained to predict LXRβ binding affinity, working alongside a directed message passing neural network (D-MPNN), a graph-based deep learning architecture that learns molecular representations directly from chemical structure. A deep learning-based drug-target interaction (DTI) predictor adds a third independent estimate of whether a given compound is likely to engage the receptor. By running a curated library of approximately 1.2 million natural products through this ensemble, the team could rank candidates not just on raw predicted potency but on the probability that the predictions would hold up experimentally.

Crucially, the pipeline did not stop at affinity. The researchers applied sequential filters for LXRβ/LXRα selectivity, ensuring that hits would preferentially activate the beta isoform and spare the liver from unwanted LXRα-driven lipogenesis. An integrated pharmacokinetic scoring step then assessed whether candidates possessed the physicochemical properties needed to reach the brain. Surviving compounds were subjected to molecular docking and MM-GBSA binding free energy calculations, which model the physical fit and energetics of each ligand inside the LXRβ binding pocket. This layered funnel, from millions of compounds down to a handful of high-confidence candidates, exemplifies how modern AI screening can compress what was once a decade-long campaign into a focused computational exercise.

Four candidates emerged from the computational gauntlet, and the team moved to the laboratory to test them. Using CCK-8 cytotoxicity assays across five glioblastoma cell lines and six normal cell models, the researchers evaluated both anti-tumor potency and therapeutic window. One compound stood out: 5,6-epoxyergosterol, an oxidized derivative of ergosterol, the fungal counterpart of cholesterol. The molecule showed potent cytotoxicity against glioma cells while sparing normal cells, exactly the selectivity profile the computational filters were designed to enforce. That a compound derived from fungal sterols, a chemical class evolutionarily tuned to interact with sterol-sensing proteins, would emerge as an LXRβ agonist is a satisfying convergence of natural product chemistry and computational prediction.

To understand how 5,6-epoxyergosterol engages its target at atomic resolution, the team ran a 200-nanosecond molecular dynamics simulation of the LXRβ-ligand complex. The simulation demonstrated remarkably stable binding throughout the trajectory, with the compound anchored by dominant hydrogen-bonding contacts to two key residues, His435 and Trp443, in the receptor’s ligand-binding domain. The free energy landscape computed from the simulation was consistent with a single dominant agonist-bound conformation, suggesting that the compound locks the receptor into an active state rather than sampling multiple binding modes. This kind of conformational stability is what medicinal chemists look for when distinguishing genuine agonists from transient binders, and it provides a structural hypothesis for how the fungal sterol activates cholesterol efflux genes.

The broader significance of the work extends beyond a single compound. The study draws on rich genomic datasets to justify its target: single-cell RNA sequencing data from 24 IDH-wildtype glioblastoma tumors comprising 7,550 cells, bulk RNA-seq data from 173 patients in the TCGA-GBM cohort, and spatial transcriptomics from the Ivy Glioblastoma Atlas Project. By grounding the computational campaign in human tumor data, the researchers ensured that the cholesterol dependency they were exploiting is not an artifact of cell culture but a feature of real disease. The approach also positions fungal natural products, an underexplored corner of chemical space compared with plant-derived compounds, as a rich source of central nervous system drug leads.

For a field that has seen no new approved systemic therapy in more than ten years, the prospect of a cholesterol-starvation strategy delivered by a brain-penetrant, LXRβ-selective natural product is genuinely exciting. The standard of care remains surgical resection followed by radiotherapy and temozolomide chemotherapy, with median survival measured in months, and recent immunotherapy and targeted therapy efforts have largely failed to move the needle. Metabolic vulnerabilities like the LXR-cholesterol axis offer a way to attack the tumor’s fundamental biochemistry, an approach that may be harder for heterogeneous tumors to escape than single-pathway inhibition, since every glioblastoma cell needs membranes.

Considerable work remains before 5,6-epoxyergosterol or its analogs reach the clinic. The current evidence rests on computational prediction, in vitro cytotoxicity, and simulation; animal pharmacokinetics, brain exposure studies, and formal selectivity profiling against the full nuclear receptor family will be essential next steps. Nevertheless, the study delivers a validated AI-driven framework for natural product drug discovery in neuro-oncology, one that other laboratories can adapt to different targets and compound libraries. If the fungal ergosterol derivatives identified here continue to perform as they move toward preclinical development, the marriage of machine learning and mycology may prove to be one of the more unexpected alliances in the fight against brain cancer.

Subject of Research: AI-guided discovery of fungal ergosterol derivatives as selective LXRβ agonists targeting cholesterol dependency in glioblastoma

Article Title: Artificial intelligence-guided discovery of fungal ergosterol derivatives as selective LXRβ agonists targeting the cholesterol dependency of glioblastoma

Article References: Li, Q., Zhang, C., Hu, T., Zhang, Z., & Wu, H. (2026). Artificial intelligence-guided discovery of fungal ergosterol derivatives as selective LXRβ agonists targeting the cholesterol dependency of glioblastoma. Molecular Diversity. https://doi.org/10.1007/s11030-026-11728-7

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11728-7

Keywords: glioblastoma, LXRβ, cholesterol metabolism, artificial intelligence, virtual screening, natural products, ergosterol, blood-brain barrier, molecular dynamics, drug discovery, neuro-oncology, machine learning